+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The role of orlistat in the treatment of obesity



The role of orlistat in the treatment of obesity



Orvosi Hetilap 146(11): 493-498



The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need drug treatment, over the diet and physical activity. Among the available medicines the inhibitors of monoamine re-uptake causes dry mouth, tachycardia, sleeplessness and elevated blood pressure, therefore, due to the frequently associated obesity and hypertension many physicians avoid using these compounds. The orlistat as a selective inhibitor of pancreatic and enteral lipase enzymes impedes the absorption of the highest calorie containing nutrients, the fats exerting beneficial effects in the treatment of obesity. The abdominal bloating and diarrhea as side effects of the drug may act as an advantage in many cases, since these happen especially in those cases when the patient neglects the previously suggested low fat diet and therefore the drug induced diarrhea and bloating may mean a feed-back for the patient in respect of the proper diet. Recent studies show many beneficial biochemical changes in obesity related pathological metabolic processes during the administration of orlistat. The authors, in their present work review in short the role of orlistat in the treatment of slimming cure.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050723467

Download citation: RISBibTeXText

PMID: 15813187


Related references

Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines. Molecular Oncology 9(3): 689-703, 2015

The role of dietary fat in obesity and therapy with orlistat. Fat digestion and absorption: 420-431, 2000

Orlistat in the treatment of obesity. Expert Opinion on PharmacoTherapy 1(4): 841-847, 2001

Orlistat in the treatment of obesity. Primary Care 30(2): 427-440, 2003

Does orlistat really offer help for the treatment of obesity?. Atencion Primaria 24(8): 445-446, 2000

Sibutramine and orlistat in the treatment of obesity. International Journal of Obesity 26(Supplement 1): S183, 2002

Currently available drugs for the treatment of obesity: Sibutramine and orlistat. Mini Reviews in Medicinal Chemistry 7(1): 3-10, 2007

Clinical value of Orlistat in the treatment of hypertension associated to obesity. International Journal of Obesity 27(Supplement 1): S101, 2003

Orlistat for the long-term treatment of obesity. Drugs of Today 35(2): 139-145, 2003

Is orlistat medically essential for the treatment of obesity?. Versicherungsmedizin 51(1): 36-37, 1999

Role of Orlistat for changing nutritional habits in patients with obesity and dyslipidemias. International Journal of Obesity 27(Supplement 1): S108, 2003

Orlistat is a well tolerated, long-term treatment for obesity. International Journal of Obesity 22(SUPPL 3): S274, 1998

A 2-year US multicentre study of orlistat in the treatment of obesity. European Heart Journal 18(ABSTR SUPPL ): 143, 1997

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes. Expert Opinion on PharmacoTherapy 6(14): 2483-2491, 2005

Benefit-risk assessment of orlistat in the treatment of obesity. Drug Safety 37(8): 597-608, 2015